Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
The phenotype and function of cells enriched in tumor-propagating activity and their relationship to the phenotypic architecture in multiple myeloma (MM) are controversial. Here, in a cohort of 30 patients, we show that MM composes 4 hierarchically organized, clonally related subpopulations, which, although phenotypically distinct, share the same oncogenic chromosomal abnormalities as well as immunoglobulin heavy chain complementarity region 3 area sequence. Assessed in xenograft assays, myeloma-propagating activity is the exclusive property of a population characterized by its ability for bidirectional transition between the dominant CD19−CD138+ plasma cell (PC) and a low frequency CD19−CD138− subpopulation (termed Pre-PC); in addition, Pre-PCs are more quiescent and unlike PCs, are primarily localized at extramedullary sites. As shown by gene expression profiling, compared with PCs, Pre-PCs are enriched in epigenetic regulators, suggesting that epigenetic plasticity underpins the phenotypic diversification of myeloma-propagating cells. Prospective assessment in paired, pretreatment, and posttreatment bone marrow samples shows that Pre-PCs are up to 300-fold more drug-resistant than PCs. Thus, clinical drug resistance in MM is linked to reversible, bidirectional phenotypic transition of myeloma-propagating cells. These novel biologic insights have important clinical implications in relation to assessment of minimal residual disease and development of alternative therapeutic strategies in MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationMaintenance of Serological Memory by Polyclonal Activation of Human Memory B Cells
Bernasconi, N. L., Traggiai, E., & Lanzavecchia, A. (2002) · Science · doi:10.1126/science.1076071 · Cited by 1,304 · cited 1×
“Genetic characterization of the clonotypic hierarchy by FISH confirmed the presence of oncogenic cytogenetic abnormalities [such as t(11;14), t(4;14) and del132526] in clonotypic CD19 cells as well as in PCs and Pre-PCs of the same patient showing that these cells are part of the same malignant clone as the CD138 PCs…”
BackgroundThe genetic architecture of multiple myeloma
Morgan, G. J., Walker, B. A., & Davies, F. E. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3257 · Cited by 913
Taussig, D. C., Miraki-Moud, F., Anjos-Afonso, F., Pearce, D. J., Allen, K., Ridler, C., Lillington, D., Oakervee, H., Cavenagh, J., Agrawal, S. G., et al. (2008) · Blood · doi:10.1182/blood-2007-10-118331 · Cited by 373
Cited by
Umezu, T., Tadokoro, H., Azuma, K., Yoshizawa, S., Ohyashiki, K., & Ohyashiki, J. H. (2014) · Blood · doi:10.1182/blood-2014-05-576116 · Cited by 600
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy
Maus, M. V., & June, C. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1433 · Cited by 265
Dobson, S. M., García-Prat, L., Vanner, R. J., Wintersinger, J., Waanders, E., Gu, Z., McLeod, J., Gan, O. I., Grandal, I., Payne-Turner, D., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1059 · Cited by 94
Maiso, P., Mogollón, P., Ocio, E. M., & Garayoa, M. (2021) · Cancers · doi:10.3390/cancers13112542 · Cited by 48
“MM cells are constantly invading new regions within the BM through induced systemic recirculation [109,110].”
BackgroundA liquid biopsy to detect multidrug resistance and disease burden in multiple myeloma
Rajeev Krishnan, S., De Rubis, G., Suen, H., Joshua, D., Lam Kwan, Y., & Bebawy, M. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0304-7 · Cited by 34
Metadata
- Authors
- Chaidos, A., Barnes, C. P., Cowan, G., May, P. C., Melo, V., Hatjiharissi, E., Papaioannou, M., Harrington, H., Doolittle, H., Terpos, E., Dimopoulos, M., Abdalla, S., Yarranton, H., Naresh, K., Foroni, L., Reid, A., Rahemtulla, A., Stumpf, M., Roberts, I., & Karadimitris, A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-01-10
- Volume
- 121
- Issue
- 2
- Pages
- 318-328
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2061650461
- Cited by
- 134
- References
- 5
- FWCI
- 8.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. https://app.cochat.ai/papers/10.1182/blood-2012-06-436220
- The paper
- Chaidos, A., Barnes, C. P., Cowan, G., May, P. C., Melo, V., Hatjiharissi, E., Papaioannou, M., Harrington, H., Doolittle, H., Terpos, E., Dimopoulos, M., Abdalla, S., Yarranton, H., Naresh, K., Foroni, L., Reid, A., Rahemtulla, A., Stumpf, M., Roberts, I., & Karadimitris, A. (2013). Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood. https://doi.org/10.1182/blood-2012-06-436220
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.